Pure Global
NCT06294912

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

A Controlled Human Malaria Infection Study to Evaluate the Antimalarial Activity of MK-7602 Against Plasmodium Falciparum Blood Stage Infection in Healthy Adult Participants
Merck Sharp & Dohme LLC·Phase 1·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Plasmodium falciparum
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Merck Sharp & Dohme LLC
Location
South Brisbane, Australia
Timeline & enrollment
Phase
Phase 1
Start date
Apr 18, 2024
End date
Mar 24, 2025
Enrollment
42 participants
Primary outcome

Parasite reduction ratio (PRR48) (Parts 1 and 2),Parasite Clearance Half-life (PCt1/2) (Parts 1 and 2),Parasite Regrowth (Parts 1 and 2),Part 1 Single dose: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of MK-7602,Part 1 Single dose: Maximum Plasma Concentration (Cmax) of MK-7602,Part 1 Single dose: Concentration at 24 Hours (C24) of MK-7602,Part 1 Single dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602,Part 1 Single dose: Elimination Half-life (t1/2) of MK-7602,Part 2 Multiple dose: Area Under the Curve Time 0 to End of the Dosing Interval (AUC0-tau) of MK-7602,Part 2 Multiple dose: Maximum Plasma Concentration (Cmax) of MK-7602,Part 2 Multiple dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602,Part 2 Multiple dose: Elimination Half-life (t1/2) of MK-7602

Summary

The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and
 safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum)
 infection.

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06294912
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06294912 through Pure Global AI's free database. This Phase 1 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Malaria. Target enrollment is 42 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.